Xenova deal

XNVAZ (U.K.) will conduct late-stage development of the XR5000 anticancer agent under an agreement with the Cancer Research Campaign (CRC) of the U.K. The drug was synthesized by the Auckland Cancer Institute and was under co-development between Auckland and CRC. The drug has demonstrated in preclinical studies the ability to inhibit cancer cell proliferation, XNVAY said. ...